Thursday, 26 April 2012 15:44

Nomura Quick Note: "Afamelanotide receives approval in Switzerland"

CUV announced that their afamelanotide product has been accepted by two health insurers in Switzerland for full reimbursement for the prophylactic treatment of patients with erythropoietic protoporphyria (EPP), a rare genetic disease causing extreme intolerance of skin to light.